If you have been reading about PPAR delta and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-09. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
1993/2614) Northampton Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2615) Bishop Auckland Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2616) Carlisle Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2617) Cheviot and Wansbeck National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2618) City Hospitals Sunderland National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2619) West Cheshire National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2620) South Kent Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2621) Stockport Acute Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2622) Guild Community Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2623) North Tyneside Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2624) Preston Acute Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2625) Tameside and Glossop Community and Priority Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2626) Hartlepool and Peterlee Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2627) Stockport Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2628) New Possibilities National Health Service Trust (Establishment) Order 1993 (S.I.
=== Treatment === Consumption of Amanita virosa is a medical emergency requiring hospitalization. There are four main categories of therapy for poisoning: preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either activated carbon or gastric lavage. However, due to the delay between ingestion and the first symptoms of poisoning, it is commonplace for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of metabolic acidosis, hypoglycemia, electrolyte imbalances, and impaired coagulation. No definitive antidote for amatoxin poisoning is available, but some specific treatments have been shown to improve survivability. High-dose continuous intravenous penicillin G has been reported to be of benefit, though the exact mechanism is unknown, and trials with cephalosporins show promise. There is some evidence that intravenous silibinin, an extract from the blessed milk thistle (Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. Silibinin prevents the uptake of amatoxins by hepatocytes, thereby protecting undamaged hepatic tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis. N-acetylcysteine has shown promise in combination with other therapies.
Mescaline use may rarely lead to hallucinogen-induced psychotic disorder (HIPD). HIPD is a type of substance-induced psychosis. Hallucinogen-induced psychotic disorder symptoms are psychosis with paranoia, delusions, hallucinations, or disorganized thinking that persist beyond the effects of the drug. HIPD due to psychedelics is most commonly seen with LSD use, but may also be caused by mescaline. Hallucinogen-induced psychotic disorder is a medical emergency. Without treatment, the psychotic state can continue for weeks or months. HIPD is treated with an atypical antipsychotic medication such as aripiprazole, quetiapine, olanzapine, or risperidone. Individuals with a personal or family history of mental health issues are at the highest risk for hallucinogen-induced psychotic disorder. The condition occurs in fewer than 1% of people with psychedelics.
Sources: en.wikipedia.org
== Research == In 2015, Merck reported results in thirteen cancer types; much attention was given to early results in head and neck cancer. As of May 2016, pembrolizumab was in phase IB clinical trials for triple-negative breast cancer (TNBC), gastric cancer, urothelial cancer, and head and neck cancer (all under the "Keynote-012" trial) and in phase II trial for TNBC (the "Keynote-086" trial). At ASCO, in June 2016, Merck reported that the clinical development program was directed to around 30 cancers and that it was running over 270 clinical trials (around 100 in combination with other treatments) and had four registration-enabling studies in process. Results of a phase III clinical trial in triple-negative breast cancer were reported in October 2019. Results of a phase II clinical trial in Merkel-cell carcinoma were reported in June 2016. Results of a clinical trial in people with untreatable metastases arising from various solid tumors were reported in 2017. A clinical phase III trial in combination with epacadostat, an Indoleamine 2,3-dioxygenase (IDO1) inhibitor to treat melanoma was completed in 2019. In 2021, researchers reported the results of a five-year follow-up study. In January 2022, a combination clinical trial of pembrolizumab and NL-201, a de novo protein undergoing a phase I clinical trial in people with advanced, relapsed or refractory solid tumors. In March 2023, Merck reported the results of NRG-GY018, a phase III clinical trial in people with stage three to four or recurrent endometrial carcinoma.
=== Abnormality battles === Players can fight in Abnormality battles, boosting the respective floor's realization level and power. Many of the Abnormalities present in-game originate from the prequel, Lobotomy Corporation. Every Abnormality battle has a certain gimmick or mechanic the player must figure out to defeat them. After completing an Abnormality battle, a new librarian will be unlocked for the floor. Including the Patron Librarian, five librarians in total will be available per floor. Players can customize a librarian's name, appearance, and combat dialogue. Completing Abnormality battles also grants Abnormality pages used in battles. The Abnormality pages can be split into two categories: Awakening and Breakdown. The Awakening Abnormality cards are the green ones and provide a small benefit with no downsides. The Breakdown Abnormality cards are red, with both a strong benefit and a downside. The severity of the downside depends on the card itself.
There exist dozens of recognized schools or orientations of psychotherapy—the list below represents a few influential orientations not given above. Although they all have some typical set of techniques practitioners employ, they are generally better known for providing a framework of theory and philosophy that guides a therapist in his or her working with a client.
An oligopeptide (oligo-, "a few"), is a peptide consisting of two to twenty amino acids, including dipeptides, tripeptides, tetrapeptides, and other polypeptides. Some of the major classes of naturally occurring oligopeptides include aeruginosins, cyanopeptolins, microcystins, microviridins, microginins, anabaenopeptins, and cyclamides. Microcystins are best studied because of their potential toxicity impact in drinking water. A review of some oligopeptides found that the largest class are the cyanopeptolins (40.1%), followed by microcystins (13.4%).
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.